Understanding SARS-COV-2 proteins is key to improve therapeutic options for COVID-19
COVID-19 has had a significant impact since the pandemic was declared by WHO in 2020, with over 3 million deaths and counting, Researchers and medical teams have been hard at work at developing strategies to control the spread of the infection, caused by SARS-COV-2 virus and treat affected patients. Of special interest to the global population is the developments of vaccines to boost human immunity against SARS-COV-2, which are based on our understanding of how the viral proteins work during the infection in host cells. Two vaccines, namely the Pfizer/BioINtech and Oxford/AZ vaccine rely on the use of delivering the gene that encodes the viral spike protein either as an mRNA or through an adenovirus vector to promote the production of relevant antibodies. The use of monoclonal antibodies has also been approved by the US Food and Drug Administration.
Read More
